

October 20, 2023

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: **524372**

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that based on the recommendation of Nomination and Remuneration Committee of the Company, the Board of Directors vide its Circular Resolution dated October 20, 2023, subject to the approval of the shareholders', approved the appointment of Mr. Arjun Dhanuka (DIN: 00454689) as Additional Director (in capacity of Non-Executive & Non-Independent), liable to retire by rotation and who shall hold office till the next general meeting or three months from the date of appointment, whichever is earlier. The Company will obtain shareholders' approval through postal ballot process by voting through electronic means only (remote e-voting) in due course of time.

Further, in compliance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, and NSE Circular No. NSE/ CML/2018/24 dated June 20, 2018, we wish to confirm that Mr. Arjun Dhanuka (DIN: 00454689) has not been debarred from holding the office of Director by virtue of any SEBI Order or any other Authority.

The details required under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are given in **Annexure A**.

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**

Marina Peter
Company Secretary
Encl. as above

Annexure A

(Disclosure as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 Dated July 13, 2023

S. No.	Particulars	Details
1.	Name of the Director	Mr. Arjun Dhanuka
2.	Reason of change viz. Appointment, resignation, removal, death or otherwise	Appointment
3.	Date of Appointment	October 20, 2023
4.	Terms of Appointment	Mr. Arjun Dhanuka (DIN: 00454689) - Additional Director (Non-Executive & Non-Independent), liable to retire by rotation and who shall hold office up to the next general meeting or three months from the date of appointment. Whichever is earlier.
5	Brief profile	<p>Mr. Arjun Dhanuka started his career with Dhanuka Laboratories Limited in September 2010. From 2010-2013 his role comprised of managing all the purchase decisions of the company. He graduated from Delhi University and is a now Whole Time Director at Dhanuka Laboratories Limited.</p> <p>In 2013, he started working with operations team of Synmedic Laboratories. After gaining relevant experience, he is presently supervising and is responsible for majority of operations at Synmedic Laboratories since 2020.</p> <p>He strives in Business development and strategy building. Mr. Dhanuka is young and dynamic person with an experience of more than a decade in the Pharmaceuticals Sector.</p>
6	Disclosure of relationships between directors	Mr. Arjun Dhanuka is nephew of Mr. Manish Dhanuka, Managing Director of the Company.